KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Status:
RECRUITING

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis

PHASE1

Kyverna Therapeutics

Cyclophosphamide
fludarabine